Semax vs Selank: Comparing Two Nootropic Research Peptides

Quick Comparison

Table of Contents

1. Introduction
2. Historical Development
3. Semax Overview
4. Selank Overview
5. Head-to-Head Comparison
6. Research Applications
7. Stability & Handling
8. Research Limitations
9. Conclusion
10. References

Introduction

Semax and Selank represent two of the most extensively studied nootropic peptides to emerge from Russian neuroscience research. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the late Soviet era and early post-Soviet period, these heptapeptides have accumulated substantial preclinical and limited clinical literature over several decades.

While both peptides are frequently discussed in nootropic research contexts, they operate through fundamentally different mechanisms: Semax primarily influences neurotrophin expression and melanocortin pathways, while Selank modulates GABAergic neurotransmission and demonstrates anxiolytic properties in animal models.

This comparative analysis examines the documented characteristics of each peptide, providing researchers with objective information based on published literature. Understanding the distinctions between these compounds is essential for appropriate experimental design and accurate interpretation of research findings.

Important Regulatory Note: Both Semax and Selank are approved prescription medications in Russia and some former Soviet states. However, neither has undergone FDA approval processes, and they are not approved for therapeutic use in the United States, European Union, or most other Western countries. All information presented here reflects research findings and does not constitute medical advice.

Historical Development

Origins at the Institute of Molecular Genetics

Both peptides emerged from extensive Soviet-era research into regulatory peptides at the Institute of Molecular Genetics (IMG) in Moscow. This research program, begun in the 1970s, sought to develop bioactive peptide fragments from larger endogenous proteins.

Semax Development Timeline

• 1970s-1980s: Initial research on ACTH fragments
• 1982: First publications on ACTH(4-7) cognitive effects
• 1990s: Development of stabilized Semax analog
• 2001: Approved as prescription medication in Russia
• 2011: Approved in Ukraine

Selank Development Timeline

• 1980s: Research begins on tuftsin analogs
• 1990s: Selank synthesized with enhanced stability
• 2009: Approved as prescription medication in Russia
• Ongoing: Continued research in anxiety and immunomodulation

Research Output

The majority of published research on both peptides originates from Russian and CIS-country institutions, with the IMG remaining the primary research center. This geographic concentration of research is an important consideration when evaluating the literature.

Semax Overview

Molecular Structure

Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-7, with an added C-terminal tripeptide Pro-Gly-Pro (PGP) sequence for enhanced stability.

Parent Sequence: ACTH(4-7) = Met-Glu-His-Phe
Semax Addition: Pro-Gly-Pro
Full Sequence:  Met-Glu-His-Phe-Pro-Gly-Pro
Length:         7 amino acids
MW:             813.93 Da

Structural Features:

• N-terminal methionine (oxidation-sensitive)
• C-terminal PGP extension provides proteolytic resistance
• Retains ACTH(4-7) nootropic activity
• Loses ACTH steroidogenic activity
• Crosses blood-brain barrier in animal studies

Proposed Mechanisms of Action

Neurotrophin Modulation

The most extensively documented mechanism involves effects on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF):

• BDNF Expression: Studies in rodent models show increased BDNF mRNA and protein levels in hippocampus and cortex following Semax administration [1, 2]
• NGF Modulation: Similar effects observed on NGF expression in certain brain regions [3]
• TrkB Signaling: Proposed downstream activation of tropomyosin receptor kinase B pathways
• Neuroplasticity: Theoretical enhancement of synaptic plasticity through neurotrophin pathways

Melanocortin System Interaction

As an ACTH-derived peptide, Semax interacts with melanocortin signaling:

• Does not bind MC1-5 receptors with high affinity
• May modulate melanocortin system indirectly
• Lacks steroidogenic activity of parent ACTH
• Proposed interactions with MC4R in some models

Additional Proposed Mechanisms

• Dopaminergic Effects: Modulation of dopamine turnover in select brain regions [4]
• Serotonergic Interactions: Effects on serotonin metabolism reported
• Gene Expression: Broad transcriptional effects observed in microarray studies [5]
• Neuroprotection: Antioxidant and anti-inflammatory effects in injury models

Research Applications

Semax has been investigated in various preclinical models:

Variants and Analogs

Several Semax variants have been developed:

• N-Acetyl Semax: Acetylated N-terminus for enhanced stability
• N-Acetyl Semax Amidate: Both termini modified
• Semax + PEG: Pegylated versions for extended half-life

Selank Overview

Molecular Structure

Selank is a synthetic heptapeptide analog of the naturally occurring immunopeptide tuftsin, with an added C-terminal tripeptide sequence.

Parent Sequence: Tuftsin = Thr-Lys-Pro-Arg
Selank Addition: Pro-Gly-Pro
Full Sequence:   Thr-Lys-Pro-Arg-Pro-Gly-Pro
Length:          7 amino acids
MW:              751.9 Da

Structural Features:

• Based on tuftsin immunomodulatory tetrapeptide
• C-terminal PGP extension (same as Semax)
• No methionine (more oxidation-stable than Semax)
• Enhanced proteolytic stability compared to native tuftsin
• Proposed blood-brain barrier penetration

Proposed Mechanisms of Action

GABAergic Modulation

The primary documented mechanism involves effects on GABA neurotransmission:

• GABA Metabolism: Studies suggest modulation of GABA synthesis and degradation enzymes [6]
• Benzodiazepine Site: Does not directly bind benzodiazepine receptors
• Allosteric Effects: Proposed indirect modulation of GABA-A receptor function
• Anxiolytic Profile: Produces anxiolytic-like effects in animal models without sedation [7]

Enkephalinase Inhibition

Selank demonstrates inhibitory effects on enkephalin-degrading enzymes:

• Enkephalin Preservation: Inhibits breakdown of endogenous enkephalins
• Opioid System Modulation: Indirect effects on opioid signaling
• Mood Effects: Proposed contribution to anxiolytic and antidepressant-like effects

Immunomodulatory Effects

Retaining properties from parent tuftsin:

• Cytokine Modulation: Effects on IL-6, IL-10, and other cytokines [8]
• Immune Cell Function: Modulation of macrophage and lymphocyte activity
• Anti-inflammatory: Proposed systemic anti-inflammatory effects

Neurotransmitter Effects

• Serotonin: Modulation of 5-HT metabolism in limbic structures [9]
• Dopamine: Effects on dopaminergic neurotransmission
• Norepinephrine: Alterations in catecholamine balance

Research Applications

Selank has been studied in various experimental contexts:

Comparison with Benzodiazepines

Unlike traditional anxiolytic compounds:

Head-to-Head Comparison

Structural Comparison

Mechanism Comparison

Semax                              Selank
──────                             ──────
BDNF/NGF Modulation                GABA Modulation
      ↓                                 ↓
Neurotrophin Signaling             Anxiolytic Effects
      ↓                                 ↓
Cognitive Enhancement    ←OVERLAP→  Cognitive Effects
      ↓                                 ↓
Neuroprotection         ←OVERLAP→  Stress Resilience
      ↓                                 ↓
Melanocortin Effects               Immunomodulation

Primary Outcome Differences

Dose Ranges in Research

Semax (Literature Ranges):

• Intranasal (Russian formulation): 50-600 mcg/dose
• Research doses (rodent): 50-600 mcg/kg
• In vitro: 0.1-100 mcM concentrations

Selank (Literature Ranges):

• Intranasal (Russian formulation): 75-300 mcg/dose
• Research doses (rodent): 100-500 mcg/kg
• In vitro: 0.1-100 mcM concentrations

Pharmacokinetic Comparison

Research Applications

Comparative Research Contexts

When Semax May Be Selected

• Neurotrophin Studies: Research examining BDNF/NGF modulation
• Cognitive Models: Memory and learning enhancement paradigms
• Stroke/Ischemia: Neuroprotection in cerebrovascular injury models
• Neurodegenerative Models: Toxin-induced neurodegeneration studies
• Attention Research: Focus and attention-related investigations

When Selank May Be Selected

• Anxiety Models: Anxiolytic compound studies
• Stress Research: HPA axis and stress response studies
• Immunology: Neuroimmune interaction research
• GABA System: GABAergic modulation studies
• Mood Research: Depression and mood disorder models

Combination Research

Some Russian studies have examined combined administration:

• Rationale: Complementary mechanisms (cognitive + anxiolytic)
• Evidence: Limited published data on combinations
• Considerations: Different optimal parameters may exist

Published Efficacy Data Summary

Semax in Animal Models

Selank in Animal Models

Stability & Handling

Storage Requirements

Reconstitution Guidelines

Semax:

• Use bacteriostatic water or sterile saline
• Prepare fresh working solutions when possible
• Protect from oxidation (minimize air exposure)
• Store reconstituted solution at 4C
• Consider N-Acetyl versions for enhanced stability

Selank:

• Reconstitute in bacteriostatic water or sterile saline
• More stable than Semax in solution
• Standard peptide handling applies
• Store at 4C after reconstitution
• Less sensitive to oxidation

Handling Comparison

Research Limitations

Geographic Concentration

A significant limitation in evaluating both peptides is the concentration of research within Russian and CIS institutions:

• Primary Research Center: Institute of Molecular Genetics, Moscow
• Publication Language: Many studies in Russian-language journals
• Independent Replication: Limited Western laboratory replication
• Potential Bias: Research concentration raises methodological concerns

Methodological Considerations

Clinical Data Limitations

Despite regulatory approval in Russia, both peptides lack:

• Randomized controlled trials meeting Western regulatory standards
• Long-term safety data
• Pharmacokinetic studies in diverse populations
• Drug-drug interaction data
• Pediatric or geriatric specific studies

Regulatory Considerations

Note: Semax is classified as a prohibited substance under WADA anti-doping regulations due to its ACTH-derived structure.

Conclusion

Summary Comparison

Key Distinctions

1. Different Parent Molecules: Semax derives from ACTH; Selank from tuftsin - fundamentally different starting points

2. Different Primary Targets: Semax focuses on neurotrophin systems; Selank on GABAergic and immune systems

3. Different Research Niches: Semax dominates cognitive and neuroprotection research; Selank leads in anxiety and stress models

4. Different Stability Profiles: Selank's lack of methionine provides superior oxidative stability

5. Different Regulatory Classifications: Semax faces WADA restrictions; Selank does not

Research Selection Framework

Consider Semax when:

• Neurotrophin modulation is the research focus
• Cognitive enhancement models are employed
• Neuroprotection paradigms are used
• BDNF pathway research is conducted

Consider Selank when:

• Anxiolytic mechanisms are studied
• GABAergic system research is conducted
• Immunomodulation is relevant
• Stress response models are used
• Better stability is needed

Final Considerations

Both Semax and Selank represent interesting research tools with substantial preclinical literature, primarily from Russian institutions. However, researchers should approach this literature with appropriate critical evaluation given the geographic concentration of research and limited independent replication.

Neither peptide is approved for therapeutic use outside of Russia and select CIS countries. The evidence base, while extensive in Russian literature, does not meet the standards typically required by Western regulatory agencies. Researchers should consider these limitations when designing experiments and interpreting results.

For investigators interested in these compounds, direct engagement with primary literature - including Russian-language publications where possible - is recommended to fully understand the current state of knowledge.

References

Semax References

1. Dolotov OV, et al. Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.

2. Agapova TY, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neurosci Lett. 2007;417(2):201-205.

3. Dolotov OV, et al. Semax prevents the death of PC-12 cells by nerve growth factor deprivation. Dokl Biol Sci. 2003;390:213-216.

4. Eremin KO, et al. Effects of Semax on dopaminergic and serotoninergic systems of the brain. Dokl Biol Sci. 2004;394:1-3.

5. Filippenkov IB, et al. Genome-wide analysis of gene expression in brain of rats after ischemic stroke and the effect of neuroprotective drug Semax. BMC Genomics. 2020;21(1):402.

Selank References

6. Semenova TP, et al. Effects of Selank on cognitive processes after damage to the catecholaminergic brain system in rats. Bull Exp Biol Med. 2007;144(5):689-691.

7. Seredenin SB, et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2010;40(2):131-137.

8. Uchakina ON, et al. Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr. 2008;108(5):71-75.

9. Semenova TP, et al. Restoration of learning ability in rats with lesions of the serotonergic system of the brain by Selank. Bull Exp Biol Med. 2006;142(6):687-689.

Comparative and General References

10. Ashmarin IP, et al. Regulatory peptides deriving from food proteins. Neurosci Behav Physiol. 2010;40(4):408-416.

11. Myasoedov NF, et al. Acth(4-7)PGP (Semax) and its analogs: the structure-activity relationships. Dokl Biol Sci. 2008;423:424-426.

12. Zolotarev YA, et al. Distribution and metabolism of Semax, an ACTH(4-10) analog, after intranasal administration. Russ J Bioorg Chem. 2006;32(1):57-63.

13. Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned reflex for active avoidance in rats. Neurosci Behav Physiol. 2003;33(7):639-643.

14. Konstantinova EV, et al. Immunotropic properties of ACTH(4-7)PGP (Semax) in stress. Bull Exp Biol Med. 2010;149(4):443-445.

15. Uchakina ON, et al. Effect of Selank on the mRNA level of interleukin genes in rat brain during the inflammation. Mol Med. 2012;(3):38-41.

16. Levitskaya NG, et al. Antiamnestic effect of Semax and tuftsin analogs. Bull Exp Biol Med. 2008;146(10):431-434.

17. Kozlovskaya MM, et al. Anxiolytic activity of Selank and its role in the regulation of adaptive behavior. Zh Vyssh Nerv Deiat. 2002;52(2):205-209.